Third Wave's Q1 Revenues Slump 15 Percent as Surge in R&D Spending Widens Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Third Wave Technologies today said first-quarter revenues slumped 15 percent as R&D spending surged 122 percent and net loss widened 34 percent.  
 
Total receipts for the three months ended March 31 decreased to $6.7 million from $7.9 million year over year.
 
Revenue from clinical molecular diagnostics products rose 27 percent to $6 million from $4.7 million, but receipts from research products declined 81 percent to $569,000 from $3 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.